Candel Therapeutics
Biotechnology ResearchView the employees at
Candel Therapeutics-
Alona Meirav Quality Engineer at Candel Therapeutics
-
Rising Star
Shawna Banducci Regulatory Data Governance and Analytics, BS, MLIS-
Greater Boston
-
Rising Star
Caitlyn Doherty Corporate Communications and Investor Relations at Candel Therapeutics-
Greater Boston
-
Rising Star
Christopher Matheny VP, Development Leader at Candel Therapeutics-
Rising Star
Carly Sautter Upstream Process Development Associate at Candel Therapeutics-
Providence, Rhode Island, United States
-
Rising Star
Overview
Candel ($CADL) is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. New discovery programs are based on the HSV platform. For more information, visit www.candeltx.com or contact us at info@candeltx.com.
-